METROPOLIS HEALTHCARE LTD – ANALYST MEET HIGHLIGHTS
#Q1FY27
Business Overview
- Metropolis has grown from a single lab to 209 laboratories and 5,000+ centres across 750 towns, with presence in 5 international markets.
- FY26 revenue stood at ₹1,646 Cr; 57% of revenue comes from B2C and the balance from B2B.
- North India contribution has increased to around 10% from 7-8% earlier and was the fastest-growing region in Q1.
- Company processes around 4,500 tests, supported by 30,000 prescribing specialists.
Industry Opportunity
- Indian diagnostics market estimated at around $11 Bn, expected to reach $28.5 Bn over the next 8 years at around 11% CAGR.
- Less than 6% of Indians have ever been diagnosed, highlighting significant headroom for testing penetration.
- Management expects gradual shift from unorganized to organized diagnostics, supported by increasing healthcare awareness, branded providers and rising demand for specialized testing.
Specialty Diagnostics
- Specialty contributes around 40-42% of revenue and management intends to grow it faster than overall business.
- Metropolis has 2,200+ specialty tests across oncology, neurology, nephrology and allergy.
- Added around 380-400 new tests over the last 15 months.
- Core Diagnostics acquisition strengthens oncology capabilities with around 350 specialized tests and access to 2,000+ oncologists.
- Specialty prescriptions also bring routine tests, improving overall revenue per patient.
- New offerings include blood-based Alzheimer's testing, hereditary cancer panels and genomics.
Genomics & Precision Medicine
- Genomics business has grown 2x in the last year.
- Company has onboarded medical geneticists and genetic counsellors to support clinicians with interpretation and counselling.
- Metropolis operates 2 CAP-accredited genomics labs, one each in West and North India.
- Orthogonal testing capability spans histopathology to genomics, allowing multiple diagnostic modalities under one roof.
- Precision medicine opportunity extends across oncology, neurology and reproductive medicine.
True Health
- True Health contributes around 20% of business currently.
- Portfolio includes illness/wellness packages, radiology, doctor consultation, diet and obesity-related services.
- Management aims to increase True Health contribution from around 18% to 25%.
- Diet plans are increasingly being designed using individual blood-test parameters.
- Obesity/vital check-up offerings can increase recurring customer visits and engagement.
Network Expansion
- Current network stands at 5,000+ centres, with around 750-800 own centres and the rest franchise-led.
- Company aims to increase collection-centre density from 1:24 to 1:35.
- Focus is on deeper penetration within existing 750 towns before entering many new markets.
- Own B2C centres will remain concentrated in the top 6-7 towns, while smaller markets will largely be franchise-led.
- Management is exploring ways to improve productivity of existing centres by using their infrastructure beyond the morning peak hours.
Radiology & Mini-Hubs
- Around 100 centres are planned to be developed into mini-hubs over the next couple of years.
- Services may include X-ray, ultrasound, 2D echo and TMT.
- Existing centres can be upgraded with limited incremental CapEx.
- Mini-hubs can additionally serve corporates and insurance-led health checks.
- Management sees scope to substantially improve productivity of existing real estate through healthcare adjacencies.
B2C, B2B & Digital
- B2C represents around 57% of revenue and grew approximately 18% in the latest quarter.
- Home collection contributes around 11-12% of revenue, with service currently covering roughly 200 PIN codes.
- Digital customers have nearly 2x lifetime value versus regular offline customers.
- B2B grew around 15% in the latest quarter, aided by the Core Diagnostics test menu.
- Digital initiatives currently contribute around 25% of business through app, website and customer platforms.
- Management continues to invest in direct-to-consumer digital acquisition and customer experience.
Technology & AI
- Company aims to become a fully technology-enabled organisation over the next 2-3 years.
- Focus areas include automation, digitisation, AI-based report summarisation and customer-service productivity.
- Management is building more technology capabilities in-house to reduce vendor dependence and increase execution speed.
- AI is also being explored for diet guidance and clinical decision support through MetroBot.
Acquisition Strategy
- Metropolis has completed around 25 acquisitions historically and has developed an integration playbook.
- Core Diagnostics was acquired as a largely breakeven business and has moved to high-single-digit EBITDA within a year.
- Management expects Core to approach company-level EBITDA margins by around Year 3.
- Future acquisitions will focus on strategic geographies or capabilities where Metropolis currently has limited presence.
Quality & Moat
- Company maintains around 99.9% proficiency score, placing it among the top laboratories globally.
- CAP accreditation and continuous external proficiency testing have been maintained for 20+ years.
- Management believes the moat is not simply laboratories or machines, but the combination of science, quality, talent, culture and execution.
- Global Reference Laboratory in Mumbai spans 38,000 sq ft, can process up to 25,000 tests/day and has 250+ scientific staff.
Growth Track Record
- Revenue CAGR over the last 3 years was 17.6%; FY26 growth was 23.6%.
- EBITDA CAGR over 3 years was 18.6%; FY26 EBITDA growth was around 23%.
- FY26 reported EBITDA margin was 24.4%, while organic margin was around 25.9%.
- Growth has been primarily volume-led, supported by moderate pricing and improving product mix.
KEY TAKEAWAY
- Strong specialty + True Health + digital growth engines, with Core integration and network productivity offering further upside.
1August 31, 2026 630
